Yellowstone Biosciences
unknown
unknown
Stage
1
Investors
About
Yellowstone Biosciences develops soluble T-cell receptor (TCR)-based biologic therapies aimed at treating cancers, with a stated focus on acute myeloid leukaemia.
Explore Yellowstone Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.